Paraganglioma
A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)
Subtype terms (2)
More specific conditions that are subtypes of Paraganglioma in the MeSH hierarchy.
- Paraganglioma, Extra-Adrenal
5 drugs (4 approved, 1 experimental)
- Pheochromocytoma
66 drugs (46 approved, 20 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (3)
Phase 2 trials (25)
- 177lu-dota0-tyr3-octreotate
- 18f-mfbg
- gallium-68-dotatate
- axitinib
- anlotinib
- olaparib
- talazoparib
- guadecitabine
- nivolumab
- pazopanib
- lanreotide
- ipilimumab
- sunitinib
- temozolomide
- cabozantinib
- dotatoc-90y
- linsitinib
- amino acids
- fludeoxyglucose f-18
- lutetium (177lu) oxodotreotide
- lutetium dotatate lu-177
- 177lu-dotatoc
- eo2401
- [203pb]vmt-α-net
- [212pb]vmt-α-net,
Phase 1 trials (13)
Other trials (2)
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (29)
- Molecular Insight Pharmaceuticals
- Advanced Accelerator Applications
- Roche
- Merck
- Exelixis
- Pfizer
- Ipsen
- Enterome
- National Cancer Institute (NCI)
- National Cancer Institute, France
- University of Pennsylvania
- Duke University
- Excel Diagnostics and Nuclear Oncology Center
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)
- Johns Hopkins University
- Sarcoma Alliance for Research through Collaboration
- Seoul National University
- Southwest Oncology Group
- University of Iowa
- University of Toronto
- Mayo Clinic
- Columbia University
- University of California, San Francisco
- Icahn School of Medicine at Mount Sinai
- Institut Gustave Roussy
- University of Texas at Houston
- Washington University in St. Louis
- European Network for the Study of Adrenal Tumours
- Vall d'Hebron Institute of Research, Galatea Clinic
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (13)
- Jubilant DraxImage Inc.
- British Columbia Cancer Agency
- Harvard University
- Emory University
- University of Washington
- University of Michigan
- University of Chicago
- University of Cincinnati
- Vanderbilt University
- Cook Children's Medical Center
- University of Wisconsin
- University of Colorado
- The University of Texas, Dallas